QOLP-22. THE INTERNATIONAL LOW GRADE GLIOMA REGISTRY: PATIENT-REPORTED QUALITY OF LIFE

The overarching goal of the International Low Grade Glioma (LGG) Registry is to allow for focused study of LGG (defined as adult grade II astrocytoma, mixed glioma, or oligodendroglioma), including quality of life (QOL). To date, enrollment is completed for 234 patients from 21 states and nine countries (US, France, United Kingdom, Canada, Australia, Hong Kong, New Zealand, Belarus and Spain). Pilot data on QOL (MOS SF-36 scale, measured from 0–100 with higher scores suggesting better QOL) are available for 112 LGG patients for whom we have confirmed treatment via medical record review. Enrolled LGG patients were predominantly White (91.2%), female (56.3%), generally otherwise healthy with only 5% reporting a co-morbid condition) and had a mean age of 36.9 years. A wide range of symptoms were reported by patients: 23.4% reported being unable to drive, 32.4% reported trouble thinking, and 35.1% reported difficulty with getting words out. To date, fifty-two percent of patients have received radiation (XRT): patients not treated with XRT at diagnosis report significantly better physical functioning than do those who received XRT, with persons receiving XRT at time of diagnosis reporting the lowest scores (p=0.003). Interestingly, patients not treated with XRT reported lower emotional and mental health scores than did those receiving XRT (p=0.02). Interpretation of these findings is limited at this point given the small sample and possible selection bias; possibilities include that the no XRT group may be more depressed/anxious for unrelated reasons, or, the absence of treatment may leave them feeling uneasy. When compared to study subjects from our prior meningioma case/control study of QOL, these results suggest significant reduction in QOL for LGG patients and possible variation by XRT treatment and thus the need to better understand these differences.